Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
•
Tumor Lysis Syndrome
•
Hospital Medicine
Do you recommend testing for G6PD deficiency in those with whom rasburicase for tumor lysis syndrome is indicated?
Answer from: at Academic Institution
G6PD deficiency is a contraindication to the use of rasburicase and should be tested for prior to the use of this drug.
Sign In
or
Register
to read more
Answer from: at Community Practice
You're supposed to test, but most do not. It's X-linked, so males are more susceptible. Certain populations are too: sub-Saharan Africa, the Mediterranean, and Southeast Asia.
Sign In
or
Register
to read more
17203
17204
Related Questions
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
Are there any special considerations you take with ESA use in hospitalized patients with ESKD who undergo stem cell transplantation?
What is your calcium level threshold for initiating targeted calcium lowering therapies for patients with an acute kidney injury believed secondary to renal vasoconstriction and volume depletion?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
Do you postpone hemodialysis for a period of time after stem cell transplantation in a hospitalized patient with ESKD?
What is your approach to electrolyte repletion for patients hospitalized with cardiac and non-cardiac conditions?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
What is your approach to managing concurrent severe SIADH and large-volume malignant ascites when aggressive volume removal appears to exacerbate both symptoms and hyponatremia?
How long do you wait before arranging AVF placement in patients with AKI who remain dialysis dependent?
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?